English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Amac: Bu calismanin amaci uterin karsinosarkomlu hastalarin yasam suresini, seroz endometrial kanserli hastalarin yasam sureleri ile karsilastirmakti. Yontem: 2002-2014 yillari arasinda endometriyal kanser nedeniyle opere edilen hastalar klinik arsivinden tarandi. Calismaya histolojik tumor tipi karsinosarkom veya seroz tip olan hastalar dahil edildi. Bulgular: Toplam hasta sayisi 99; bunlarin 53’unde karsinosarkom, 46’sinda seroz histoloji saptandi. Medyan hastaliksiz sagkalim suresi karsinosarkomda 20 (2-27) ay ve seroz tipte 36 (3-180) aydi (Log-Rank testi p=0,156). Medyan sagkalim suresi karsinosarkom icin 28 (4-170) ay, seroz icin 46 (3-180) aydi (p=0,105). Bes yillik genel sagkalim orani, karsinosarkom histolojisinde %41,2 iken, seroz histolojide %55,4 idi. Nuksten sonra, karsinosarkom histolojisi olan hastalar ortalama 8 (1-19) ay, seroz histolojisi olanlar ortalama 14 (2-43 ay) yasamislardi (p=0,090). Sonuc: Log-Rank test analizi sonuclarina gore, uterin karsinosarkomlu ve seroz endometriyal kanserli hastalar arasinda istatistiksel olarak anlamli bir sagkalim farki bulunmadi. Bununla birlikte, hastaliksiz sagkalim, genel sagkalim ve nuks sonrasi sagkalim suresi seroz histolojide karsinosarkomdan daha uzundur.

COMPARISON OF OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL IN SEROUS ENDOMETRIAL CANCER AND UTERINE CARCINOSARCOMA